Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer
2010

FBXW7/hCDC4-β Methylation and Breast Cancer Prognosis

Sample size: 161 publication 10 minutes Evidence: moderate

Author Information

Author(s): Akhoondi Shahab, Lindström Linda, Widschwendter Martin, Corcoran Martin, Bergh Jonas, Spruck Charles, Grandér Dan, Sangfelt Olle

Primary Institution: Karolinska Institute

Hypothesis

Is FBXW7/hCDC4 promoter methylation associated with prognosis in breast cancer?

Conclusion

FBXW7/hCDC4-β methylation is linked to a favorable prognosis in breast cancer despite its association with high-grade tumors.

Supporting Evidence

  • 51% of primary breast tumors showed FBXW7/hCDC4-β promoter methylation.
  • Methylation was associated with improved survival in patients with lymph node metastasis.
  • FBXW7/hCDC4-β methylation was linked to lower expression of the gene.
  • Statistical analysis showed significant differences in survival rates based on methylation status.

Takeaway

This study found that a specific change in the DNA of breast cancer cells can help doctors predict how well a patient will do, even if the cancer looks aggressive.

Methodology

The study analyzed FBXW7/hCDC4-β expression and promoter methylation in 161 breast cancer tumors using various statistical methods.

Limitations

The study was limited by the different treatment protocols used in the two cohorts.

Participant Demographics

Median age of participants was 64 years, with a range from 33 to 94.

Statistical Information

P-Value

P = 0.017

Confidence Interval

95% CI 0.23 to 1.23

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/bcr2788

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication